Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Bladder Cancer Test From KDx Diagnostics Gets CE Mark

Bladder Cancer Test From KDx Diagnostics Gets CE Mark

Jul 01, 2020
|
staff reporter

NEW YORK – KDx Diagnostics announced late on Tuesday that it has received the CE mark for its urine-based URO17 Bladder Cancer Recurrence test for bladder cancer.

As a result, the test can be marketed in Europe and other countries that recognize the designation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
15
Featured Webinar

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.

What's Popular?

In Cancer

  1. FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

  2. Burning Rock Adds New Data Supporting Cancer Screening Liquid Biopsy, Automated NGS Products

    Premium

  3. Tempus Gets CE Mark for xT Tumor Sequencing Assay

  4. Three Investment Banks Initiate Coverage of Biodesix

  5. HTG Molecular Completes 1-For-15 Reverse Stock Split

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.